Literature DB >> 3257271

The art gene product of human immunodeficiency virus is required for replication.

E Terwilliger1, R Burghoff, R Sia, J Sodroski, W Haseltine, C Rosen.   

Abstract

A mutation that alters the initiation codon of the art gene of the human immunodeficiency virus renders the virus replication defective. The replication defect of this mutation can be complemented in trans by the art gene product. These findings indicate that the art protein is essential for replication and, as such, represents a good target for development of new antiviral agents that could be useful in the control of human immunodeficiency virus infection.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3257271      PMCID： PMC250587     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  25 in total

1.  Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

Authors:  J D Lifson; M B Feinberg; G R Reyes; L Rabin; B Banapour; S Chakrabarti; B Moss; F Wong-Staal; K S Steimer; E G Engleman
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Immunoglobulin gene transcription is activated by downstream sequence elements.

Authors:  C Queen; D Baltimore
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

4.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

5.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

6.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

9.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.

Authors:  F P Siegal; C Lopez; G S Hammer; A E Brown; S J Kornfeld; J Gold; J Hassett; S Z Hirschman; C Cunningham-Rundles; B R Adelsberg
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728
View more
  48 in total

Review 1.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

2.  Automatic and quantitative measurement of protein-protein colocalization in live cells.

Authors:  Sylvain V Costes; Dirk Daelemans; Edward H Cho; Zachary Dobbin; George Pavlakis; Stephen Lockett
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

3.  Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev.

Authors:  S Kubota; R Furuta; M Maki; M Hatanaka
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Suboptimal provirus expression explains apparent nonrandom cell coinfection with HIV-1.

Authors:  Christelle Brégnard; Gregory Pacini; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

6.  Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo.

Authors:  Dirk Daelemans; Sylvain V Costes; Stephen Lockett; George N Pavlakis
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

7.  Generation and characterization of infectious chimeric clones between human immunodeficiency virus type 1 and simian immunodeficiency virus from an African green monkey.

Authors:  R Shibata; H Sakai; T Kiyomasu; A Ishimoto; M Hayami; A Adachi
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

8.  Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.

Authors:  E T Dayton; D A Konings; D M Powell; B A Shapiro; L Butini; J V Maizel; A I Dayton
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: new insights into the domain structure of Rev and Rex.

Authors:  E Böhnlein; J Berger; J Hauber
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Structural requirements for trans activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: importance of base pairing, loop sequence, and bulges in the tat-responsive sequence.

Authors:  S Roy; N T Parkin; C Rosen; J Itovitch; N Sonenberg
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.